239 related articles for article (PubMed ID: 15768377)
1. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
Pietruck F; Kiel G; Birkel M; Stahlheber-Dilg B; Philipp T
Biopharm Drug Dispos; 2005 May; 26(4):135-41. PubMed ID: 15768377
[TBL] [Abstract][Full Text] [Related]
2. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
5. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
[TBL] [Abstract][Full Text] [Related]
6. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
Hoy SM; Keating GM
Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
[TBL] [Abstract][Full Text] [Related]
7. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
Schaefer F; van de Walle J; Zurowska A; Gimpel C; van Hoeck K; Drozdz D; Montini G; Bagdasorova IV; Sorof J; Sugg J; Teng R; Hainer JW;
J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
[TBL] [Abstract][Full Text] [Related]
9. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
Sever P
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
[TBL] [Abstract][Full Text] [Related]
10. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
Takahara M; Shiraiwa T; Shindo M; Arai A; Kusuda Y; Katakami N; Kaneto H; Matsuoka TA; Shimomura I
Hypertens Res; 2014 Sep; 37(9):852-7. PubMed ID: 24739538
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
13. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
14. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
Elmfeldt D; George M; Hübner R; Olofsson B
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
[TBL] [Abstract][Full Text] [Related]
15. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
Ogihara T; Arakawa K
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic drug interaction studies with candesartan cilexetil.
Jonkman JH; van Lier JJ; van Heiningen PN; Lins R; Sennewald R; Högemann A
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S31-5. PubMed ID: 9331003
[TBL] [Abstract][Full Text] [Related]
18. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.
Zuschke CA; Keys I; Munger MA; Carr AA; Marinides GN; Flanagan TL; Cushing DJ; Hayes JL; Michelson EL
Clin Ther; 1999 Mar; 21(3):464-74. PubMed ID: 10321416
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
20. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II.
Vidt DG; White WB; Ridley E; Rahman M; Harris S; Vendetti J; Michelson EL; Wang R;
J Hum Hypertens; 2001 Jul; 15(7):475-80. PubMed ID: 11464257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
